Ewing’s sarcoma: diagnostic, prognostic, and therapeutic implications of molecular abnormalities
- Correspondence to: Dr S A Burchill, Candlelighter’s Children’s Cancer Research Laboratory, Cancer Research UK Clinical Centre, St James’s University Hospital, Beckett Street, Leeds LS9 7TF, UK; s.a.burchill{at}leeds.ac.uk
- Accepted 7 August 2002
Abstract
The identification of the non-random chromosome rearrangements between the EWS gene on chromosome 22q12 and members of the ETS gene family in Ewing’s sarcoma, peripheral primitive neuroectodermal tumour, Askin tumour, and neuroepithelioma has been a key advance in understanding their common histogenesis and defining the Ewing’s sarcoma family of tumours (ESFT). In addition to improvements in diagnosis and potentially the stratification of patients for risk, biological investigations of these gene fusions may define targets for much needed therapeutic strategies to eliminate minimal residual disease or metastatic disease. Insight into their relation with other oncogenic events in ESFT will advance risk group analysis and ultimately may improve clinical management and survival for patients with this disease.
- ESFT, Ewing’s sarcoma family of tumours
- Euro EWING 99, European Ewing tumour working initiative of national groups 99
- FISH, fluorescent in situ hybridisation
- pPNET, peripheral primitive neuroectodermal tumour
- RT-PCR, reverse transcriptase polymerase chain reaction
